Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)

Prospective Observational Study on Stelara Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)

The main purpose of this study is to assess ustekinumab's ability to induce clinical response and remission ("effectiveness") at Week 16 and remission at Week 52 and Week 104 in participants with Crohn's disease (CD). Response and remission will be assessed using clinical parameters. Retention rate at week 52 and 104 will also be studied.

Study Overview

• Status: Completed
• Conditions: Crohn Disease
• Intervention / Treatment: Drug: Ustekinumab

• Study Type: Observational
• Enrollment (Actual): 114

Contacts and Locations

Study Locations

• Sweden
  • Örebro, Sweden, SE-70185
    • Universitetssjukhuset Örebro

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Participants with a confirmed Crohn's disease (CD) aged over 18 years treated with ustekinumab.

Description

Inclusion Criteria:

• Participant has a diagnosis of CD confirmed by investigator
• Participants with active CD who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic therapy or have medical contraindications to such therapies
• The participant must sign informed consent before enrollment in the study. The consent form permits extraction of data from SWIBREG at baseline and during participation of the study and linkages to the Patient Registry (Patientregistret), SCB's registry USA for occupational details (Longitudinell integrationsdatabas for sjukforsakrings- och arbetsmarknadsstudi er), the Social Insurance registry on long-term sick leave (Forsakringskassans register gallande sjukskrivningar) and the Prescription registry (Lakemedelsregistret)
• The participant must have been initiated on treatment with ustekinumab within the last 2 weeks (that is including those who already discontinued) or started on ustekinumab treatment less than (<) 3 months ago if treatment start was documented in SWIBREG within 2 weeks of onset and has a record of Harvey Bradshaw Index (HBI) when starting ustekinumab

Exclusion Criteria:

• The participant is enrolled in a clinical trial (randomized or non-randomized) in which the treatment of CD is dictated by a study protocol. If the participant is participating in another observational study (non-interventional), the participant may be included in this observational study
• Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 60 days before the start of the study or the first data collection time point
• Participants who started ustekinumab despite contraindications for use
• Participants with planned stop of treatment with ustekinumab within 24 months from onset of treatment, that is bridging to other treatment or pregnancy planned

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Participants with Crohn's Disease (CD); Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.

Drug: Ustekinumab; Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants with Clinical Response at Week 16, Based on Harvey Bradshaw Index (HBI)	Clinical response for Crohn's disease (CD) is assessed by Harvey Bradshaw Index (HBI) and is defined as decrease of 3 points in baseline HBI score. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease and, score is presented as: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).	Week 16
Percentage of Participants with Clinical Remission at Week 16, Based on HBI	Clinical remission for CD is assessed by HBI and is defined as HBI less than (<)5. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease and, score indicates: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).	Week 16
Percentage of Participants with Clinical Remission at Week 52, Based on HBI	Clinical remission for CD is assessed by HBI and is defined as HBI <5. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease and, score is presented as: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).	Week 52
Percentage of Participants with Clinical Remission at Week 104, Based on HBI	Clinical remission for CD is assessed by HBI and is defined as HBI <5. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease and, score is presented as: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).	Week 104

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants with Clinical Response at Week 52 and 104, Based on HBI	Clinical response for CD is assessed by HBI and is defined as decrease of 3 points in baseline HBI score. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease and, score is presented as: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).	Week 52 and 104
Percentage of Participants with Clinical Remission at Week 52 and 104 who are Remitters at 16 Weeks	Clinical remission for CD is assessed by HBI and is defined as HBI <5. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease and, score is presented as: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).	Week 52 and 104
Percentage of Participants with Clinical Remission at Week 104 who are Remitters at 52 Weeks	Clinical remission for CD is assessed by HBI and is defined as HBI <5. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease and, score is presented as: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).	Week 104
Percentage of Participants with Clinical Remission at Week 52 and 104 who are Responders at 16 Weeks	Clinical remission for CD is assessed by HBI and is defined as HBI <5. Responders are defined as the participants with decrease of 3 points in baseline HBI score. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease.	Week 52 and 104
Percentage of Participants in Clinical Remission Overtime	Clinical remission for CD is assessed by HBI and is defined as HBI <5. HBI consists of clinical parameters: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicates more severe disease.	Up to Week 104
Percentage of Participants with Corticosteroid Free Remission at Week 52 and 104	Participants on corticosteroids at baseline will be analyzed according to the percentage of participants in remission at week 52 and 104 without corticosteroids to assess corticosteroids free remission.	Week 52 and 104
Participant's Time off Corticosteroids	Duration for which participants were off from corticosteroids will be determined.	Up to week 104
Percentage of Participants in Every 12 weeks/8 weeks (q12 w/q8 w) maintenance groups at Week 16	Percentage of participants in q12 w/q8 w maintenance groups will be determined at Week 16.	Week 16
Percentage of Participants on Initial q12 w Maintenance Dose Escalated from q12 w to q8 w in Year 1 and 2	Percentage of participants on initial q12 maintenance dose escalated from q12 w to q8 w in Year 1 and 2 will be determined.	Year 1 and 2
Percentage of Participants with Dose Optimization	Percentage of participants with dose optimized to other dose than 90 milligram (mg) q8 w/q12 w in maintenance in Year 1 and 2 will be determined.	Year 1 and 2
Average Maintenance Dose per Month	Average maintenance dose (in mg) taken per month will be determined.	Week 52 and 104
Mean Change from Baseline in Fecal Calprotectin (fCal) Levels at Week 16, 52 and 104	Mean change from baseline in fCal (inflammatory biomarker) levels will be determined.	Baseline, Week 16, 52 and 104
Mean Change from Baseline in C-reactive Protein (CRP) Levels at Week 16, 52 and 104	Mean change from baseline in C-reactive protein (CRP) (inflammatory biomarker) levels will be determined.	Baseline, Week 16, 52 and 104
Percentage of Participants with fCal Less Than (<)250 milligram per kilogram (mg/kg)	Percentage of participants with fCal <250 mg/kg will be determined.	Week 16, 52 and 104
Percentage of Participants with fCal levels <250 mg/kg at Week 16, 52 and 104	Percentage of participants with fCal levels <250 mg/kg at Week 16, 52 and 104 will be determined in total and amongst participants with fCal levels greater than (>)250 mg/kg at baseline.	Week 16, 52 and 104
Percentage of Participants with Normalization of Plasma-CRP (P-CRP)	Percentage of participants with normalization of P-CRP in in participants with abnormal P-CRP at baseline will be reported. Normalization of P-CRP is defined as the high-sensitive (Hs)-CRP level <3 milligram per Liter (mg/L) or CRP below threshold of abnormal CRP concentration.	Week 16, 52 and 104
Change from Baseline in Short Health Scale (SHS) Score at Week 16, 52 and 104	Quality of life will be assessed by SHS score. SHS is a health related quality of life (HRQoL) questionnaire in which the participants rate the disease impact on 4 important aspects of subjective health (symptoms, function, worry, and general well-being). Responses are scored on 100-mm visual analogue scales and presented as individual scores for each of the four questions. The scores are then added for a total score. Total score ranges from 0 (low disease activity) to 100 (high disease activity).	Baseline, Week 16, 52 and 104
Change from Baseline in EuroQoL 5-Dimension 5-Level Health Status (EQ-5D-5L) Questionnaire at Week 16, 52 and 104	Quality of life will be assessed by EQ-5D-5L score. The EQ-5D-5L descriptive system comprises following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of 5 dimension is divided into 5 levels of perceived problems (Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems, and Level 5: extreme problems). The participant selects an answer for each of 5 dimensions considering response that best matches his or her health "today". The descriptive system can be represented as a health state.	Baseline, Week 16, 52 and 104
Change from Baseline in EQ-5D-5L Visual Analog Scale (VAS) at Week 16, 52 and 104	The EQ-VAS self-rating scale records respondent's own assessment of his or her overall health status at time of completion, on a scale of 0 (worst imaginable health) to 100 (best imaginable health).	Baseline, Week 16, 52 and 104
Change from Baseline in the Presence of Extra Intestinal Manifestations at Week 16, 52 and 104	Change in the presence of extra intestinal manifestations, that is arthralgia, peripheral arthritis, anchylosing spondylitis, uveitis, erythema nodosum, pyoderma gangrenosum, primary sclerosing cholangitis, psoriatic arthritis and psoriasis will be determined.	Baseline, Week 16, 52 and 104
Healthcare Resource: Number of Imaging Procedures	Number of imaging procedures completed as a part of healthcare resources used in participants will be reported.	Up to week 104
Healthcare Resource: Number of Laboratory Test	Number of Laboratory tests completed as a part of healthcare resources used in participants will be reported.	Up to Week 104
Healthcare Resource: Number of Surgical Procedures	Number of surgical procedures completed as a part of healthcare resources used in participants will be reported.	Up to Week 104
Healthcare Resource: Number of Dual Energy X-ray Absorptiometry (DEXA) Scans	Number of DEXA scans performed as a part of healthcare resources used will be reported.	Up to Week 104
Healthcare Resource: Number of Participants with Endoscopies Performed	Number of participants with endoscopies performed as a part of healthcare resources used will be reported.	Up to Week 104
Healthcare Resource: Number of Days of Hospitalization	Number of days of hospitalization (defined as number of days from the day of admission to discharge) as a part of healthcare resources used will be reported.	Up to Week 104
Healthcare Resource: Number of Sick-Leaves	Number of sick-leaves taken by participants as a part of healthcare resources used will be reported.	Up to Week 104
Healthcare Resource: Number of Participants Using Concomitant Treatment	Number of participants using concomitant treatment as a part of healthcare resources used will be reported.	Up to Week 104
Healthcare Resource: Number of Health Care Visits	Number of health care visits to nurses, dieticians and doctors as a part of healthcare resources used will be reported.	Up to Week 104
Number of Participants with Malignancy	Number of participants with malignancy developed during the study will be reported.	Up to Week 104
Number of Participants Requiring Antibiotics for any Infection Occurred During the Study	Number of participants requiring antibiotics for any infection occurred during the study will be reported.	Up to Week 104

Collaborators and Investigators

• Sponsor: Janssen-Cilag Ltd.
• Investigators: Study Director: Janssen-Cilag Ltd. Clinical Trial, Janssen-Cilag Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): October 25, 2017
• Primary Completion (Actual): November 22, 2020
• Study Completion (Actual): November 22, 2020

Study Registration Dates

• First Submitted: March 28, 2018
• First Submitted That Met QC Criteria: April 11, 2018
• First Posted (Actual): April 12, 2018

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 31, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Intestinal Diseases; Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Inflammatory Bowel Diseases; Crohn Disease; Dermatologic Agents; Ustekinumab
• Other Study ID Numbers: CR108430; CNTO1275CRD4006 (Other Identifier: Janssen-Cilag Ltd.)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No